MIAMI & BARRANQUILLA, Colombia / Nov 10, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023.
The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results.
To access the call, please use the following information:
Date: | Thursday, November 16, 2023 | |
Time: | 10:30 a.m. ET | |
Webcast: | ||
Toll Free dial-in number: | 1-844-204-8586 | |
Toll/International dial-in number: | 1-412-317-6346 | |
HD Web Phone: | ||
Conference ID: | Procaps Group |
The conference call will be broadcast live and available for replay here and via Procaps’ investor relations website.
A telephone replay will be available approximately two hours after the call and will run through November 23, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 4127390.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
| Last Trade: | US$1.01 |
| Daily Volume: | 0 |
| Market Cap: | US$113.950M |
December 20, 2024 December 03, 2024 June 28, 2024 December 26, 2023 November 29, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
